Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 | O75899 | 2/20 | 0.52 |
| ▸ | GABBR1 | Q9UBS5 | 2/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.50 |
| ▸ | HTR2A | P28223 | 4/20 | 0.50 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.47 |
| ▸ | HRH1 | P35367 | 2/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1985899 | 1.00 | GABBR2 (0.52) | GABBR2GABBR1TAAR1HTR2AAOC3 | |
| SCHEMBL19908550 | 1.00 | GABBR2 (0.52) | GABBR2GABBR1TAAR1HTR2AAOC3 | |
| SCHEMBL17892059 | 0.88 | CHRNB2 (0.55) | GABBR2GABBR1TAAR1HTR2AAOC3 | |
| SCHEMBL4948330 | 0.88 | HTR2A (0.49) | GABBR2GABBR1TAAR1HTR2AAOC3 | |
| SCHEMBL1263573 | 0.86 | AOC3 (0.48) | TAAR1HTR2AAOC3HRH1LMNA | |
| SCHEMBL28873446 | 0.86 | HTR2A (0.51) | GABBR2GABBR1TAAR1HTR2AHRH1 | |
| SCHEMBL9921479 | 0.85 | HRH1 (0.56) | GABBR2GABBR1TAAR1HTR2AAOC3 | |
| SCHEMBL17484100 | 0.85 | HRH1 (0.56) | GABBR2GABBR1TAAR1HTR2AAOC3 | |
| SCHEMBL11343335 | 0.84 | HTR2A (0.54) | GABBR2GABBR1TAAR1HTR2AHRH1 | |
| SCHEMBL11343665 | 0.84 | HTR2A (0.54) | GABBR2GABBR1TAAR1HTR2AHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10577363-B2 | Substituted piperidine compounds | Epizyme, Inc. (US) | 2020-03-03 | — | — | US | disclosed |
| US-10266526-B2 | Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer | Epizyme, Inc. (US) | 2019-04-23 | — | — | US | disclosed |
| US-9944589-B2 | Cycloproplyamine derivatives useful as inhibitors of histone demethylases KDM1A | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2018-04-17 | — | — | US | disclosed |
| US-20170362217-A1 | Substituted Piperidine Compounds | Epizyme, Inc. (US) | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10577363-B2 | Substituted piperidine compounds | SMYD3, SMYD2, SNRPD3 | GABBR2 2012/4885GABBR1 2638/4885TAAR1 3266/4885 |
| US-20170362217-A1 | Substituted Piperidine Compounds | SMYD3, SMYD2, SNRPD3 | GABBR2 2012/4885GABBR1 2638/4885TAAR1 3266/4885 |
| US-10266526-B2 | Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer | SMYD3, SMYD2, SNRPD3 | GABBR2 2825/4885GABBR1 3404/4885TAAR1 4297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.